CLAIMS

1. Use of an anti-Allergin-1 antibody in the manufacture of an immunity enhancing agent for the treatment of cancer.

2. The use according to claim 1, wherein the anti-Allergin-1 antibody suppresses immunosuppressive intracellular signaling of Allergin-1.

3. The use according to claim 2, wherein the anti-Allergin-1 antibody is an anti-human Allergin-1 antibody.

4. The use according to claim 2 or claim 3, wherein the anti-Allergin-1 antibody is a monoclonal antibody.

5. The use according to claim 4, wherein the anti-Allergin-1 monoclonal antibody is of IgG_1 or IgG_4 isotype.

6. The use according to claim 4 or claim 5, wherein the anti-Allergin-1 monoclonal antibody is an antibody fragment selected from the group consisting of Fab, Fab', Fv, scFv and $(Fab')_2$ fragments.

7. The use according to any one of claims 4 to 6, wherein the anti-Allergin-1 monoclonal antibody is a humanized or human antibody.

8. The use according to claim 4, wherein the anti-Allergin-1 monoclonal antibody is a humanized or human anti-human Allergin-1 monoclonal IgG_1 or IgG_4 antibody.

9. The use according to claim 2 or claim 3, wherein the anti-Allergin-1 antibody is an Allergin-1 multispecific antibody recognizing two or more different epitopes present on
one Allergin-1 molecule.

10. The use according to any one of claims 1 to 9, wherein the cancer is solid cancer or hematologic cancer.

11. The use according to claim 10, wherein the solid cancer is one or more selected from malignant

melanoma, non-small cell lung cancer, small cell lung cancer, head and neck cancer, renal cell cancer, clear cell renal cell cancer, breast cancer, ovarian cancer, ovarian clear cell adenocarcinoma, bone and soft tissue sarcoma, glioblastoma, gliosarcoma, nasopharyngeal cancer, uterine cancer, anal cancer, colorectal cancer, hepatocellular cancer, esophageal cancer, pancreatic cancer, stomach cancer, urothelial cancer, prostate cancer, fallopian tube cancer, primary peritoneal cancer, pleural mesothelioma and myeloproliferative syndrome.

12. The use according to claim 10, wherein the hematologic cancer is one or more selected from multiple myeloma, non-Hodgkin lymphoma, Hodgkin lymphoma, acute myeloid leukemia and chronic myeloid leukemia.

13. The use according to any one of claims 1 to 12, which is to be administered to a cancer patient unresponsive to an anti-cancer drug.

14. The use according to claim 13, wherein the anti-cancer drug is a tumor immunotherapeutic agent.

15. The use according to claim 14, wherein the tumor immunotherapeutic agent is one or more selected from an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-PD-L2 antibody, a PD-L1 fusion protein, a PD-L2 fusion protein, an anti-CTLA-4 antibody, an anti-LAG-3 antibody, an anti-Tim3 antibody, an anti-KIR antibody, an anti-BTLA antibody, an anti-TIGIT antibody, an anti-VISTA antibody, an anti-CD137 antibody, an anti-OX40 antibody, an anti-HVEM antibody, an anti-CD27 antibody, an anti-GITR antibody, an anti-CD28 antibody, an anti-CCR4 antibody and an anti-CD4 antibody.

16. The use according to claim 15, wherein the anti-PD-1 antibody is Nivolumab, REGN-2810, Pembrolizumab, PDR-001, BGBA317, STI-A1110 or AMP-514.

17. The use according to claim 15, wherein the anti-PD-L1 antibody is Atezolizumab, Avelumab, Durvalumab or BMS-936559.

18. The use according to claim 15, wherein the anti-CTLA-4 antibody is Ipilimumab or Tremelimumab.

19. The use according to claim 15, wherein the PD-L2 fusion protein is AMP-224.

20. The use according to any one of claims 1 to 19, wherein one or more anti- cancer drugs are to be

further administered.

21. The use according to claim 20, wherein the anti-Allergin-1 antibody and the anti-cancer drug in different preparations are to be administered.

22. The use according to claim 20, wherein the anti-Allergin-1 antibody and the anti-cancer drug in one preparation is to be administered.

23. The use according to any one of claims 20 to 22, wherein the anti-cancer drug is a tumor immunotherapeutic agent.

24. The use according to claim 23, wherein the tumor immunotherapeutic agent is one or more selected from an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-PD-L2 anti-body, a PD-L1 fusion protein, a PD-L2 fusion protein, an anti-CTLA-4 antibody, an anti-LAG-3 antibody, an anti-Tim3 antibody, an anti-KIR antibody, an anti-BTLA antibody, an anti-TIGIT antibody, an anti-VISTA antibody, an anti-CD137 antibody, an anti-OX40 anti-body, an anti-HVEM antibody, an anti-CD27 antibody, an anti-GITR antibody, an anti-CD28 antibody, an anti-CCR4 antibody and an anti-CD4 antibody.

25. The use according to claim 24, wherein the anti-PD-1 antibody is Nivolumab, REGN-2810, Pembrolizumab, PDR-001, BGBA317, STI-A1110 or AMP-514.

26. The use according to claim 24, wherein the anti-PD-L1 antibody is Atezolizumab, Avelumab or Durvalumab.

27. The use according to claim 24, wherein the anti-CTLA-4 antibody is Tremelimumab.

28. The use according to claim 24, wherein the PD-L2 fusion protein is AMP-224.